Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Mereo Biopharma Group Plc ( (MREO) ).
On February 17, 2026, Mereo BioPharma received notice from Nasdaq that its American Depositary Shares had failed to maintain the required minimum bid price of $1.00 for 30 consecutive business days, placing the company out of compliance with Nasdaq’s listing standards. The ADSs will continue to trade under the MREO ticker while the company has until August 17, 2026, to regain compliance, with the possibility of an additional 180-day grace period or, failing that, a potential delisting process that could include an appeal, although business operations are currently unaffected by the notice.
The company must achieve a closing bid price of at least $1.00 for a minimum of 10 consecutive business days within the compliance window for Nasdaq to deem it back in good standing. If it cannot meet the bid price threshold or other relevant listing criteria, Mereo could face delisting from the Nasdaq Capital Market, a development that would affect its market visibility and access to U.S. investors, even though its operations are said to remain unchanged for now.
The most recent analyst rating on (MREO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Mereo Biopharma Group Plc stock, see the MREO Stock Forecast page.
Spark’s Take on MREO Stock
According to Spark, TipRanks’ AI Analyst, MREO is a Neutral.
Overall score is weighed down primarily by weak financial performance (large losses and ongoing cash burn despite a low-leverage balance sheet) and bearish technicals (below major moving averages with negative MACD). Valuation offers limited support due to negative earnings and no provided dividend yield.
To see Spark’s full report on MREO stock, click here.
More about Mereo Biopharma Group Plc
Mereo BioPharma Group plc is a biopharmaceutical company whose American Depositary Shares trade on the Nasdaq Capital Market under the symbol MREO. The company focuses on developing therapeutic products and accesses U.S. capital markets through its Nasdaq listing, which is important for its investor base and financing flexibility.
Average Trading Volume: 15,247,271
Technical Sentiment Signal: Sell
Current Market Cap: $59.17M
For detailed information about MREO stock, go to TipRanks’ Stock Analysis page.